PARAGON-HF Response Score Calculator

Clinical calculation support · Verify results before clinical use

Patient parameters

Enter baseline clinical and laboratory values.

Exploratory only
Equation coding retained from original template: male = 1, female = 0.
Reset calculator

Clinical context and limitations

PARAGON-HF compared sacubitril/valsartan with valsartan in patients with heart failure and LVEF of at least 45%. Its primary endpoint was total heart-failure hospitalizations and cardiovascular death—not a validated individual probability of response derived from the nine inputs in this calculator.

The supplied equation uses hand-assigned coefficients and a logistic transformation. The original template does not provide a derivation dataset, full regression specification, calibration assessment, discrimination statistics, or external validation. Therefore, its output cannot be interpreted as an evidence-based probability, risk category, or treatment recommendation.

Important distinctions

  • Calculated output: arithmetic output from the legacy equation.
  • Clinical interpretation: no validated interpretation or cutoff is established for this equation.
  • Treatment decision: should be based on the patient's clinical profile, applicable guidelines, contraindications, tolerability, and shared decision-making—not this index.

About the trial evidence

PARAGON-HF did not demonstrate a statistically significant reduction in its primary composite endpoint in the overall trial population. Prespecified subgroup analyses suggested treatment-effect heterogeneity, including by sex and LVEF; these findings are not equivalent to validation of the score reproduced here.

References

Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2019;381:1609–1620. DOI: 10.1056/NEJMoa1908655. Primary PARAGON-HF trial report.
McMurray JJV, Jackson AM, Lam CSP, et al. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation. 2020;141:338–351. DOI: 10.1161/CIRCULATIONAHA.119.044491. Prespecified subgroup analysis; it does not validate the legacy score.
Clinical disclaimer: This educational calculator reproduces an unvalidated exploratory equation from the supplied source code. The displayed linear index and logistic transform must not be used as a clinical prediction model, as evidence of individual treatment benefit, or as a substitute for current guidelines and professional clinical judgment.